The combined pharmacological inhibition of SIRT1 (by TV-6) and BCR-ABL1 (by IM) decreases cell proliferation, promotes apoptosis of CML progenitors and impairs CML engraftment in immunodeficient mice [95]. Here, SIRT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.